This Phase 2 study is testing an experimental drug called ACR-368 for people with high-grade endometrial adenocarcinoma (a type of uterine cancer). Researchers want to see how well ACR-368 works, either alone or with a very low dose of gemcitabine (another drug that may make cancer cells more sensitive to treatment). You could be eligible if you are an adult woman with this type of cancer. The study aims to enroll about 350 participants. Success will be measured by how much the tumors shrink or stop growing over time. The current status of the study is unclear.

Study design

This is an open-label Phase 2 study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll about 350 participants.

What's involved

You would receive treatment until your disease gets worse, you experience unacceptable side effects, or you withdraw from the study. Tumor response will be checked every 8 weeks for up to 2 years.

Compensation

Not stated in the trial record.

Follow-up

Your tumor response will be assessed every 8 weeks from the start of the study through 2 years or until death.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.